
Cingulate (CING) Stock Forecast & Price Target
Cingulate (CING) Analyst Ratings
Bulls say
Cingulate is a clinical-stage biopharmaceutical company with a positive outlook, as potential approval and commercialization of its first-line stimulant medications for ADHD and anxiety in mid to late 2026 could act as strong catalysts for the stock. Additionally, the company's current valuation is attractive, with a BUY rating and a 12-month price target of $55 based on NPV analysis, representing significant upside from the current share price. However, there are some risks to consider, including balance sheet and liquidity risks, failure of clinical trials, regulatory approval, and competition.
Bears say
Cingulate is a clinical-stage biopharmaceutical company with a PDUFA approval decision date on May 31, 2026, for its lead asset CTx-1301, a once-daily, multi-core proprietary tablet formulation of dexmethylphenidate for the treatment of ADHD. Although the company has stated that discussions with the FDA may delay approval, the drug's efficacy and safety data, along with bioequivalence data, make it an eminently approvable product candidate. However, estimates for 2026 EPS have been adjusted from $(2.54) to $(1.52) based on potential delays.
This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.
Cingulate (CING) Analyst Forecast & Price Prediction
Start investing in Cingulate (CING)
Order type
Buy in
Order amount
Est. shares
0 shares